Who Should and Who Should Not Be Vaccinated Against Human Papillomavirus Infection?
|
|
- Joel Lewis
- 5 years ago
- Views:
Transcription
1 CERVICAL CANCER REVIEW Who Should and Who Should Not Be Vaccinated Against Human Papillomavirus Infection? Jorma Paavonen, MD, Department of Obstetrics and Gynecology, Helsinki University Hospital, Haartmaninkatu 2 Received 11/6/2010, Reviewed 14/7/2010, Accepted 27/7/2010 Keywords: Human Papillomavirus Infection, Cervical cancer, Cross protection, Vaccination DOI: /ejom BACKGROUND Approximately 0 years ago Dr. Harald zur Hausen and others from the German Cancer Research Center in Heidelberg, published the landmark papers of the link between high risk human papillomavirus (HPV) types 16/18 and cervical cancer. This discovery of cervical cancer led to Blackburn, Greider and Szostak being awarded the Nobel Prize for medicine in Prophylactic HPV vaccines are targeted against HPV 16 and 18, which are highly carcinogenic and more carcinogenic than other so called high-risk HPV types. The attributable proportion for HPV16/18 in cervical cancer is approximately 70%. The next common cancer associated HPV types 45 and 1 are relatively closely related to HPV16/18. CORRESPONDENCE Jorma Paavonen, MD Department of Obstetrics and Gynecology, Helsinki University Hospital, Haartmaninkatu Helisnki, Finland Tel: jorma.paavonen@hus.fi There are still approximately 60,000 cervical cancer cases annually in Europe, a strikingly high prevalence rate. The incidence of cervical cancer in European countries is highly variable since only few countries have organised mass screening programs. Another megatrend is the increasing incidence of cervical cancer in young women, particularly cervical adenocarcinoma. Cervical adenocarcinoma is even more aggressive than cervical squamous cell carcinoma. HPV types 16, 18 and 45 account for more than 90% of cervical adenocarcinomas. Cervical adenocarcinoma is also more difficult to detect by Pap smear. HPV18 is more dominant in cervical adenocarcinoma than in cervical squamous cell carcinoma. HPV cancer disease burden extends beyond cervix (1). Other anogenital cancers related to high-risk HPV types include anal cancer, vaginal and vulvar cancer and penile cancer. Also a considerable proportion of oropharyngeal cancers or cancers of the oral cavity are HPV related. In these other cancers the same high-risk HPV types dominate, HPV16 in particular. Although vulvar cancer is six times and vaginal cancer 20 times less common than cervical cancer globally, these cancers collectively account for approximately six per cent of all gynaecological cancers. It is concerning that high grade vulvar intraepithelial neoplasia (VIN2/) is increasing and the mean age of these patients is decreasing. Dysplastic lesions of the vagina or the vulva often occur in women who have a pervious history of CIN. Identical HPV DNA integration sites have been found in vaginal or vulvar and cervical samples of lesions from patients with a prior history of high grade CIN or cervical cancer. This suggests that dysplastic lesions in the female lower genital tract may emerge as monoclonal lesions from a transformed cell population derived from the cervix (2). Unfortunately there is no screening test for VIN. VIN lesions are often multiple and show high recurrence rate. The risk for progression is significant and may be even higher than that of cervical intraepithelial neoplasia (CIN) 2/. High grade VIN is treated by surgery. Surgical treatment is often disfiguring and mutilating, in addition, the disease burden of genital warts is enormous (). HPV Virus-like particle vaccines HPV virus-like particles (VLP) were discovered approximately 20 years ago, and this discovery rapidly led to the development of prophylactic VLP vaccines. Currently two prophylactic vaccines are available. Quadrivalent vaccine (Gardasil, Merck) is targeted against HPV6/11/16/18. The bivalent vaccine (Cervarix, GlaxoSmithKline) is targeted against HPV16/18. (Figure 1) These vaccines have different adjuvants. Clinical phase III efficacy trials have been performed in 1-14 countries in four continents among year old women (4-10). The quadrivalent HPV vaccine has also been studied in women aged years with no history of genital warts or cervical disease (11). ISSN
2 HEALTHCARE BULLETIN CERVICAL CANCER Figure 1: Preventive HPV Vaccines Cervarix Gardasil Vaccine Type HPV-16 and HPV-18 VLP L1 capsid component HPV-6/11/16/18/VLP L1 capsid component Concentration 20 μg HPV μg HPV μg HPV 6 20 μg HPV μg HPV μg HPV 18 Adjuvant AS04: 500 μg Aluminium Hydroxide 50 μg -O-desacyl-4 - monophosphoryl lipid A Alum: 225 μg Aluminium Amorphous Aluminium Hydroxyphosphate Sulfate AAHS Age Range* years years *Phase III efficacy trials Highlights of the global phase III efficacy trials Multinational phase III trials of a quadrivalent HPV L1 VLP vaccine were conducted in the Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I and II trials which enrolled more than 17,000 women aged years. The impact of the prophylactic quadrivalent vaccine on all HPV-associated genital disease was studied in a population that approximates sexually naive women, so called negative to 14 types population (12) and in a mixed population of HPV exposed and HPV unexposed women, so called intention to treat group (1). Vaccine or placebo was given at day one, month two and month six. The average follow-up was.6 years. In the negative to 14 HPV types population vaccination was up to 100% effective in reducing HPV16/18 related high grade cervical, vulvar and vaginal lesions and HPV6/11 related genital warts. Reduction in disease end points irrespective of causal HPV type in the negative to 14 types population was 42.9% for CIN2, 4.0% for CIN, 82.8% for genital warts and 77.1% for VIN2/ or VaIN2/. In the intention to treat population vaccination also reduced disease end-points related to the vaccine HPV types (54.8%, 45.%, 79.5% and 78.5%, respectively). Reductions irrespective of causal HPV type in the intention to treat population were lower. Pap abnormalities, colposcopy procedures and cervical definitive therapies reduced 20%-40% in both populations, and generally more in the negative to 14 types population. A multinational phase III trial of the bivalent HPV16/18 AS04 adjuvanted vaccine, the Papilloma TRIal against Cancer In young Adults (PATRICIA) trial, was performed among 18, year old women vaccinated at months 0, 1, and 6 (8, 9). The total vaccinated cohort (TVC) included all women receiving at least one vaccine dose regardless of their baseline HPV status, representing general population of sexually active young women. The TVC naive population included women with normal cytology and who were HPV DNA negative for 14 oncogenic HPV types and seronegative for HPV16/18, approximating the primary target population for organised vaccination programs (that is young women before sexual debut). The mean follow-up was 4.9 months after the third dose. Vaccine efficacy against CIN2+ associated with HPV16/18 was 92.9% in the primary analysis and 98.1% in an analysis in which probable causality to HPV type was assigned in lesions infected with multiple oncogenic types. Vaccine efficacy against CIN2+ irrespective of HPV type in lesions was 0.4% in the TVC and 70.2% in the TVC naive. Corresponding values against CIN+ were.4% n the TVC and 87.0% in the TVC naive. The bivalent vaccine also substantially reduced colposcopy referrals and cervical excision procedures in both the TVC and TVC naive. (Figure 2) The quadrivalent HPV vaccine has been efficacious in women aged years not infected with the relevant HPV types at enrolment. The efficacy against disease or infection related to HPV16/18 was 8.1% in the per protocol population but only 22.6% in the intention-to-treat population since infection and disease were often present at baseline. No vaccine related serious adverse events were recorded (11). 4
3 WHO SHOULD AND WHO SHOULD NOT BE VACCINATED AGAINST HUMAN PAPILLOMAVIRUS INFECTION? Figure 2: Overall Vaccine Efficacy Against CIN2+ and CIN+ irrespective of HPV type in the lesion Vaccine n Control n Vaccine efficacy % (96.1% CI) P-value TVC naïve* CIN2+ CIN ( ) 87.0 ( ) TVC** CIN2+ CIN ( ).4 ( ) *Vaccine N=5449; Control N=546; **Vaccine N=8667; Control N=8682 TCV= All women who received 1 dose of study vaccine; Case counting began the day after 1st vaccination TVC-naïve= Received 1 dose of study vaccine; Normal cytology at Month 1; HPV DNA negative for all oncogenic types at Month 0; Seronegative for HPV- 16/18 at Month 0; Case counting began the day after 1st vaccination Cross protection L1 of HPV16/18 share homology with other high-risk types. Therefore antibodies to HPV16/18 L1 VLPs may be able to neutralise virions of related types. This cross-protection may increase the impact of the vaccines. In the phylogenetic tree of papillomaviruses HPV1 is relatively closely related to HPV16, and HPV45 is closely related to HPV18. HPV45 and 1 are the next important cancer related HPV types after HPV16/18. It should be noted however that most of this cross protection was based on protection against HPV 1, not HPV 45 (12-1). In the FUTURE trials cross protection against HPV1/45 related high grade CIN was 58.7%. Cross protection against five most common high risk types was 2.5% and against 10 most common high risk types again 2.5%. Cross protection by the bivalent vaccine against HPV1/45 related CIN2+ was 100%, and against HPV1//45/52/58 related high grade CIN 68.2% and against 10 most common high risk HPV types related CIN2+ was 68.4%. In the bivalent vaccine trial vaccine efficacy was approximately 7% against CIN2+ lesions associated exclusively with non-vaccine HPV types. Globally 70% of cervical cancer is estimated to be caused by HPV16/18 with the remaining 0% caused by other oncogenic HPV types. Thus, this analysis suggests that cross protective efficacy of the bivalent vaccine could represent 11%-16% additional protection against cervical cancer that is greater than the protection provided by vaccine efficacy against HPV16/18 (9). Safety Both quadrivalent vaccine and the bivalent vaccine have been proven to be safe with no significant safety signals based on the large global multinational randomised efficacy trials. This applies to serious adverse events, medically significant conditions, new onset autoimmune diseases, and pregnancy outcomes. Post-licensure surveillance is ongoing. (Figure ) HPV positivity did not increase local or general symptoms after vaccination. Similarly there is no evidence that vaccination affects the progression of pre-existing lesions. Additional findings from clinical trials Among women positive for 1- HPV vaccine types before vaccination the quadrivalent HPV vaccine protected against cervical neoplasia caused by remaining types (14). This supports vaccination of the general population without pre-screening. Vaccination also induces robust immune memory (15). These findings suggest that efficacy of the quadrivalent vaccine will be long lasting. The role of immune memory in the context of vaccine efficacy is not fully understood. Natural HPV infection induced antibodies may not provide complete protection over time. However, the immune response to the HPV vaccines may prevent reinfection or reactivation of disease with vaccine HPV types (16). Women who have been treated for CIN continue to be at increased risk of cervical cancer. Results with the quadrivalent vaccine suggest that vaccinated women who had definitive therapy for CIN had significantly decreased risk for new cervical disease after definitive therapy (17). Should HPV vaccine be given to men? In October 2009 the FDA approved the use of the quadrivalent vaccine in boys and men aged 9-26 years for the prevention of genital warts (18). Additional data are expected to be forthcoming on the efficacy of the quadrivalent vaccine to prevent anal intraepithelial neoplasia on homosexual men. In general, the vaccine may work as well in boys as in girls since both vaccines are effective in preventing infection with the vaccine HPV types in women naive to these types. The vaccines are probably effective in boys as well. 5
4 HEALTHCARE BULLETIN CERVICAL CANCER Figure : Safety: Bivalent vaccine TVC Vaccine N = 9,19 % Control N = 9,25 % Serious Adverse Events (SAE) Medically significant conditions New onset autoimmune disease Selected pregnancy outcomes Congenital anomalies Spontaneous abortions Mean follow-up for safety analysis in TVC was 40.8 Months post Dose 1 Medically significant conditions=conditions prompting physician visits Pregnancies: 1804 in vaccine group, 1802 in control group The benefit may be firstly reduction of HPV associated disease burden in boys and men and secondly prevention of HPV transmission to women. Mathematical modelling has demonstrated that if vaccine coverage in women remains low vaccination of boys is important for so called herd immunity which then ultimately may lead to eradication of the high-risk vaccine HPV types (19). However, if vaccine coverage in girls is more than 70%, the added value from the population point of view may be relatively small. This also means that the cost effectiveness of so called catch-up vaccination programs is limited and achievement of major public health takes longer time. As with HPV transmission from women to men it has not yet been proven that male vaccination would reduce transmission of HPV from men to women. In addition cost-effectiveness analysis of including boys in an HPV vaccination program seems to exceed conventional thresholds of cost-effectiveness (20). It should be emphasised however, that vaccination eradicated rubella only after both genders were vaccinated. The same situation may hold for HPV as well. HPV vaccination reason for caution The disease end-point in the efficacy trials has been high grade cervical, vulvar or vaginal pre-cancer, not cancer (21). High grade precancer can be considered a valid surrogate marker for cancer, and it is usually managed by surgery. The question whether the current vaccines ultimately prevent cancer and death can be answered in just a few years by linking the large registries of vaccines and cancer registries in countries with high-quality cancer registries such as Scandinavian countries. If the vaccines are effective against high grade pre-cancer it is more than likely that vaccination will prevent cancer as well. Another open question is the duration of protection against HPV infection. Antibody levels seem to plateau and stay well above the levels induced by natural HPV infection for at least 8 years. We do not know yet whether booster vaccination is needed. Most likely, the vaccination will also change screening practices. In the vaccine era HPV DNA testing will be undoubtedly introduced in primary screening. One important question is also so called type replacement. This means that if vaccination eradicates HPV16/18 is it then possible that other high-risk types fill the so called ecological niche. However HPV is a stable DNA virus so that such type replacement is highly unlikely to happen in any foreseeable future. However, it is difficult to predict the likelihood of HPV type replacement following implementation of HPV vaccination programs. A competitive advantage for specific high risk HPV types over other genital HPV types in the unvaccinated population is possible and this certainly warrants further studies and monitoring or post marketing surveillance following universal mass vaccination programs. Many remaining questions will be answered based on the ongoing community randomised controlled phase IV trial in Finland among 5, year old females and males enrolled from communities. HPV disease burden beyond cervical and other anogenital cancers HPV has also been linked to oropharyngeal cancers and cancers of the oral cavity. Head and neck cancer is the sixth most common cancer worldwide with approximately 640,000 new cases per year. The incidence is increasing rapidly as reported from Sweden, United States and United Kingdom. The incidence of these oropharyngeal squamous cell carcinomas seems to be accounted for by rising HPV related carcinomas. 6
5 WHO SHOULD AND WHO SHOULD NOT BE VACCINATED AGAINST HUMAN PAPILLOMAVIRUS INFECTION? Sexual transmission of HPV primarily through orogenital intercourse might be the reason for the increase in incidence. For instance, a pooled analyses of eight multinational observational studies comparing more than 5,600 cases of head and neck cancer and more than 6,000 found that the risk of developing oropharyngeal carcinoma was associated with the history of six or more lifetime sexual partners, four or more lifetime oral sex partners and an earlier age at first sexual intercourse. Thus, HPV vaccination programs may also affect the incidence of HPV related oropharyngeal carcinomas which is an important added value or bonus effect to be considered in modelling exercises of vaccination programs or cost-effectiveness calculations. CONCLUSIONS Current prophylactic HPV vaccines are highly effective against high grade cervical pre-cancer that is related to the vaccine HPV types or irrespective of HPV type in HPV naive target populations. HPV vaccines should therefore be given before sexual debut for maximum benefit. The vaccines show significant cross-protection against other nonvaccine HPV types. This extended protection provides added value which is most relevant to the full public health impact of the vaccines and in particular so called catch-up vaccination in the general population of sexually active young women. The vaccines demonstrate favourable safety profile and no association with adverse pregnancy outcome. Ongoing surveillance and monitoring HPV vaccination programs remains important. REFERENCES De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceshi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 2009;124: Vinokurova S, Wentzensen N, Einenkel J, Klaes R, Ziegert C, Melsheimer P, et al. Clonal history of papillomavirus-induced dysplasia in the female lower genital tract. JNCI 2005;97: Kjaer SK, Tran TN, Sparen P, Tryggvadottir L, Munk C, Dasbach E, Liaw K-L, Nygård M. The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries. JID 2007;196: The Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. NEJM 2007;56: The Future II Study Group; Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007;69: Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papilloma virus to prevent anogenital disease. NEJM 2007;56: Joura AE, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, 18) LI virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007;69: Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM, et al. Efficacy of a prophylactic adjuvant bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;69: Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow S-N, Apter D, Kitchener H, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvant vaccine against cervical infection and precacner caused by oncogenic HPV types (PATRICIA): final analysis of a doubleblind, randomised study in young women. Lancet 2009;74: Munoz N, Kjaer SK, Sigurdsson K, Iversen O-E, Hernandez- Avila M, Whleeler CM, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. JNCI 2010;102:25-9. Munoz N, Manalastas R Jr, Pitisuttithum P, Tresukosol D, Monsonego J, Clavel C, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged years: a randomised, double-blind trial. Lancet 2009;7: Brown DR, Kjaer SK, Sigurdsson K, Iversen O-E, Hernandez-Avila M, Wheeler CM, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged years. JID 2009;199: Wheeler CM, Kjaer SK, Sigurdsson K, Iversen O-E, Herandez- Avila M, Perez G, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged years. JID 2009;199: The FUTURE II Study Group. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. JID 2007:196: Olsson S-E, Villa LL, Costa RLR, Petta CA, Andrade RP, Malm C, et al. Infection of immune memory following administration of a prophylactic quadrivalent human papillomacirus (HPV) types 6/11/16718 L1 virus-like particle (VLP) vaccine. Vaccine 2007; 25: Olsson S-E, Kjaer SK, Sigurdsson K, Iversen O-E, Hernandez-Avila M, Wheeler CM, et al. Evaluation of quadrivalent HPV6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Human Vaccines 2009;5: Joura EA, Garland SM, Paavonen J, Ferris DG, Perez G, Ault KA, et al. Impact of a quadrivalent human papillomavirus types 6/11/16/18 vaccine after treatment for cervical and vulval disease (submitted). Palefsky JM. Human papillomavirus-related disease in men: not just a women s issue. J Adolesc Health 2010;46:S12-S19. Lehtinen M, French KM, Dillner J, Paavonen J, Garnett G, et al. Sound implementation of human papillomavirus vaccination as a community randomized trial. Therapy 2008;5: Kim JJ, Goldie SJ. Const effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ;9:909. Haug CJ. Human papillomavirus vaccination reason for caution. NEJM 2008;59: Mehanna H, Jones TM, Gregoire V, Ang KK. Oropharyngeal carcinoma related to human papillomavirus. BMJ 2010;40: Näsman A, Attner P, Hammarstedt L, Du J, Eriksson M, Giraul G, et al. Incidence of human paillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int J Cancer 2009;125:
An update on the Human Papillomavirus Vaccines. I have no financial conflicts of interest. Case 1. Objectives 10/26/2016
An update on the Human Papillomavirus Vaccines Karen Smith-McCune Professor, UCSF Department of Obstetrics, Gynecology and Reproductive Sciences John Kerner Endowed Chair I have no financial conflicts
More informationSCCPS Scientific Committee Position Paper on HPV Vaccination
SCCPS Scientific Committee Position Paper on HPV Vaccination Adapted from Joint Statement (March 2011) of the: Obstetrical & Gynaecological Society of Singapore (OGSS) Society for Colposcopy and Cervical
More informationFocus. A case. I have no conflicts of interest. HPV Vaccination: Science and Practice. Collaborative effort with Karen Smith-McCune, MD, PhD 2/19/2010
HPV Vaccination: Science and Practice George F. Sawaya, MD Professor Department of Obstetrics, Gynecology and Reproductive Sciences Department of Epidemiology and Biostatistics Director, Colposcopy Clinic,
More informationINTRODUCTION HUMAN PAPILLOMAVIRUS
INTRODUCTION HUMAN PAPILLOMAVIRUS Professor Anna-Lise Williamson Institute of Infectious Disease and Molecular Medicine, University of Cape Town National Health Laboratory Service, Groote Schuur Hospital
More informationThe promise of HPV vaccines for Cervical (and other genital cancer) prevention
The promise of HPV vaccines for Cervical (and other genital cancer) prevention CONTROVERSIES IN OBSTETRICS GYNECOLOGY & INFERTILITY Barcelona March 27 F. Xavier Bosch Catalan Institute of Oncology CURRENT
More informationCommonly asked questions on human papillomavirus vaccine
Hong Kong J. Dermatol. Venereol. (2008) 16, 12-17 Review Article Commonly asked questions on human papillomavirus vaccine PKS Chan Recently, human papillomavirus (HPV) vaccine has been attracting the attention
More informationPrevention strategies against the human papillomavirus: The effectiveness of vaccination
Available online at www.sciencedirect.com Gynecologic Oncology 107 (2007) S19 S23 www.elsevier.com/locate/ygyno Prevention strategies against the human papillomavirus: The effectiveness of vaccination
More informationUp date. sexually transmission HPV HPV HPV. high-risk HPV HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 66, 68 HPV
Up date Kei Kawana HPV HPV HPV HPV HPV6, 11 HPV HPV HPV vaccine preventable diseasevpd HPV HPV HPV DNA 8 HPV 100 genomic type HPV HPV HPV HPV HPV 1 sexually transmission HPV HPV 2 HPV high-riskhpv HPV16,
More informationHuman papilloma virus vaccination: practical guidelines
International Journal of Research in Medical Sciences Yadav K et al. Int J Res Med Sci. 2014 Nov;2(4):1799-1803 www.msjonline.org pissn 2320-6071 eissn 2320-6012 Brief Report DOI: 10.5455/2320-6012.ijrms201411118
More informationImpact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women
DOI: 1.193/jnci/djp534 Advance Access publication on February 5, 21. The Author 21. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org.
More informationThe future of cervical cancer screening. Contents of this presentation. Prevention of cervical cancer. Prevention of cervical cancer HPV vaccines
The future of cervical cancer screening Pekka Nieminen, MD, PhD, Associate Professor Dept. Obst. & Gyn., Helsinki University Hospital, Finland Contents of this presentation Prevention of cervical cancer
More informationPreventive Vaccines against HPV. Paris, 2 April 2015 Yvonne Deleré, MD (former) Immunization Unit, Robert Koch Institute, Berlin
Preventive Vaccines against HPV Paris, 2 April 2015 Yvonne Deleré, MD (former) Immunization Unit, Robert Koch Institute, Berlin Content 1. HPV associated diseases 2. Preventivevaccines Efficacy Safety
More informationOpinion: Cervical cancer a vaccine preventable disease
Opinion: Cervical cancer a vaccine preventable disease Leon Snyman Principal specialist at the Department of Obstetrics and Gynaecology, Gynaecological Oncology unit, University of Pretoria and Kalafong
More informationPathology of the Cervix
Pathology of the Cervix Thomas C. Wright Pathology of the Cervix Topics to Consider Burden of cervical cancer 1 Invasive Cervical Cancer Cervical cancer in world Second cause of cancer death in women Leading
More informationHUMAN PAPILLOMAVIRUS VACCINES AND CERVICAL CANCER
HUMAN PAPILLOMAVIRUS VACCINES AND CERVICAL CANCER Virology The Human Papillomavirus (HPV) is a relatively small virus, belonging to the family Papillomaviridae, containing circular double-stranded DNA
More informationLargest efficacy trial of a cervical cancer vaccine showed Cervarix protects against the five most common cancercausing
FOR IMMEDIATE RELEASE Largest efficacy trial of a cervical cancer vaccine showed Cervarix protects against the five most common cancercausing virus types Published in The Lancet: Additional efficacy could
More informationQuadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil Ò )
ADIS DRUG EVALUATION Drugs 2010; 70 (18): 2449-2474 0012-6667/10/0018-2449/$55.55/0 ª 2010 Adis Data Information BV. All rights reserved. Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant
More informationHPV-Associated Disease and Prevention
HPV-Associated Disease and Prevention Odessa Regional Medical Center May 28, 2015 Erich M. Sturgis, MD, MPH Professor Department of Head & Neck Surgery Department of Epidemiology Christopher & Susan Damico
More informationCervical cancer is the second most common cancer affecting women worldwide. Cervical
Continuing Education Column Human Papillomavirus Vaccine Mi-Kyung Kim, MD Jae Hong No, MD Yong -Sang Song, MD Department of Obstetrics and Gynecology, Seoul National University College of Medicine E -
More informationHPV vaccination How to promote women s health and prevent cancer with good screening strategies, hosted by NFOG
HPV vaccination How to promote women s health and prevent cancer with good screening strategies, hosted by NFOG Pekka Nieminen MD, PhD and Miriam Elfström, PhD Chief Physician, Associate Professor Dept.Obstetrics
More informationHPV vaccination Where are we now? Where are we going? Margaret Stanley Department of Pathology Cambridge
HPV vaccination Where are we now? Where are we going? Margaret Stanley Department of Pathology Cambridge 1 Disclosure Statement Dr. Margaret Stanley has acted as a consultant and advisor for Merck Sharp
More informationHuman Papillomavirus
Human Papillomavirus Dawn Palaszewski, MD Assistant Professor of Obstetrics and Gynecology University of February 18, 2018 9:40 am Dawn Palaszewski, MD Assistant Professor Department of Obstetrics and
More informationUpdate on Clinical Trials for Bivalent HPV Vaccine
Update on Clinical Trials for Bivalent HPV Vaccine A/Prof Quek Swee Chong Medical Director Parkway Gynaecology Screening & Treatment Centre Gleneagles Hospital, Singapore Disclosure of interest Swee Chong
More informationPRODUCT INFORMATION GARDASIL 9. [Human Papillomavirus 9-valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) vaccine, Recombinant]
PRODUCT INFORMATION GARDASIL 9 [Human Papillomavirus 9-valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) vaccine, Recombinant] DESCRIPTION GARDASIL 9 *, Human Papillomavirus 9-valent Vaccine, Recombinant,
More informationA Short Review on Human Papillomavirus Vaccines
A Short Review on Human Papillomavirus Vaccines KF TAM MRCOG HYS NGAN FRCOG Division of Gynaecological Oncology, Department of Obstetrics and Gynaecology, Queen Mary Hospital, The University of Hong Kong,
More informationHuman papillomavirus
2012 Antigen Review for the New Zealand National Immunisation Schedule: Human papillomavirus Auckland UniServices Limited A wholly owned company of The University of Auckland Prepared for: New Zealand
More informationThe HPV Vaccination Programme Early intervention in cancer prevention Northern Ireland
The HPV Vaccination Programme Early intervention in cancer prevention Northern Ireland Immunisations Very cost effective intervention Give vaccine before exposure to disease UK has life course approach
More informationFOR ELECTRONIC DISRIBUTION ONLY
Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised
More informationHuman papillomavirus and vaccination for cervical cancer
Human papillomavirus and vaccination for cervical cancer Dorothy Machalek Department of Microbiology and Infectious Diseases Royal Women s Hospital, Melbourne, Australia VIRUSES AND CANCER Responsible
More informationUICC HPV and CERVICAL CANCER CURRICULUM. UICC HPV and Cervical Cancer Curriculum Chapter 5. Application of HPV vaccines Prof. Suzanne Garland MD
UICC HPV and CERVICAL CANCER CURRICULUM 01 Chapter 5. Application of HPV vaccines Director of Microbiological Research Director of Clinical Microbiology and Infectious Diseases The Royal Women's Hospital
More informationProphylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges
REVIEW 10.1111/j.1469-0691.2012.03946.x Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges M. Poljak Institute of Microbiology and Immunology,
More informationPrevention of HPV Disease What we know in 2012
Prevention of HPV Disease What we know in 2012 1952 HPV was discovered 1978 - HPV was first identified in skin cancer History 1982 - connection between HPV 16 and 18 and cervical cancer was established
More informationStrategies for HPV Vaccination in the Developing World
Coalition to STOP Cervical Cancer Governing Council ISSUE BRIEF Strategies for HPV Vaccination in the Developing World Introduction HPV vaccine represents an important opportunity to significantly reduce
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent
More informationHPV AND CERVICAL CANCER
HPV AND CERVICAL CANCER DR SANDJONG TIECHOU ISAAC DELON Postgraduate Training in Reproductive Health Research Faculty of Medicine, University of Yaoundé 2007 INTRODUCTION CERVICAL CANCER IS THE SECOND
More informationUpdate of the role of Human Papillomavirus in Head and Neck Cancer
Update of the role of Human Papillomavirus in Head and Neck Cancer 2013 International & 12 th National Head and Neck Tumour Conference Shanghai, 11 13 Oct 2013 Prof. Paul KS Chan Department of Microbiology
More informationEradicating Mortality from Cervical Cancer
Eradicating Mortality from Cervical Cancer Michelle Berlin, MD, MPH Vice Chair, Obstetrics & Gynecology Associate Director, Center for Women s Health June 2, 2009 Overview Prevention Human Papilloma Virus
More informationCERVICAL CANCER VACCINE DEVELOPMENT
Sexual Health for Marian Saville due 30 th November. CERVICAL CANCER VACCINE DEVELOPMENT Ian H Frazer The University of Queensland Diamantina Institute, Princess Alexandra Hospital, Ipswich Road, Woolloongabba
More informationProfessor Margaret Stanley
19 th Annual Conference of the British HIV Association (BHIVA) Professor Margaret Stanley University of Cambridge 16-19 April 2013, Manchester Central Convention Complex 19 th Annual Conference of the
More information2 HPV E1,E2,E4,E5,E6,E7 L1,L2 E6,E7 HPV HPV. Ciuffo Shope Jablonska HPV Zur Hausen HPV HPV16. HPV-genome.
58 2 pp.155-164 2008 2. HPV 20 HPV HPV HPV HPV HPV L1 HPV-DNA 16/18 2 HPV16 /18 6/11 4 2 100 1 Ciuffo 1907 20 Shope 1933 Raus 1934 20 70 Jablonska HPV Orth HPV5 8 1983 zur Hausen HPV16 1 HPV-genome 920-8641
More informationwarts or papillomas in the upper respiratory tract, particularly the larynx, and that is associated with extensive morbidity (Table 1). RISK FACTORS G
CONCISE REVIEW FOR CLINICIANS HPV AND VACCINATION Human Papillomavirus and Vaccination CHRISTINE M. HUANG, MD On completion of this article, you should be able to (1) review pathophysiology and transmission
More informationHPV FREE IDAHO. Fundamentals of HPV Bill Atkinson, MD MPH
HPV FREE IDAHO Fundamentals of HPV Bill Atkinson, MD MPH You are the Key to HPV Cancer Prevention William Atkinson, MD, MPH Associate Director for Immunization Education Immunization Action Coalition February
More informationNew paradigm for prevention of cervical cancer
European Journal of Obstetrics & Gynecology and Reproductive Biology 130 (2007) 25 29 Expert opinion New paradigm for prevention of cervical cancer GlaxoSmithKline has developed a bivalent vaccine, Cervarix
More informationCOLLEGE WOMEN S PERCEPTIONS OF HPV VACCINES AND THEIR PERCEIVED BARRIERS TO ADOPTION OF VACCINATION
COLLEGE WOMEN S PERCEPTIONS OF HPV VACCINES AND THEIR PERCEIVED BARRIERS TO ADOPTION OF VACCINATION Pacific Global Health Conference October 10, 2012 L. Yoda, A. Katz, D. Nahl, D. Streveler, R. Busse &
More informationHPV vaccines. Margaret Stanley Department of Pathology Cambridge
HPV vaccines Margaret Stanley Department of Pathology Cambridge 1 Disclosure Statement Dr. Margaret Stanley has acted as a consultant and advisor for Merck Sharp & Dohme, GlaxoSmithKline, and Sanofi Pasteur
More informationGlobal HPV Disease Burden : Rationale for Vaccine
Global HPV Disease Burden : Rationale for Vaccine Muhammet Nabi Kanibir, MD Regional Medical Director Medical Affairs, MSD-Vaccines Muscat, September 2011 HPV Disease Burden Global Regional What do we
More informationHPV vaccine perspectives Dr. David Prado Cohrs
HPV vaccine perspectives Dr. David Prado Cohrs Universidad Francisco Marroquín, Guatemala President of the Sexually Transmitted Diseases Committee, SLIPE Disclosure statement The presenter has received
More informationWhat is the Safety and Efficacy of Vaccinating the Male Gender to Prevent HPV Related Neoplastic Disorders in Both the Male and Female Genders
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2011 What is the Safety and Efficacy of Vaccinating
More informationCervical Cancer 8/20/2008. New genital HPV infections are commonest amongst young adults. Development of antibody to HPV capsids after HPV infection
Preventing cervical cancer from bench to bedside and beyond Ian Frazer Diamantina Institute, The University of Queensland, Brisbane, Australia Cervical Cancer Second commonest cause of cancer in women
More informationHPV the silent killer, Prevention and diagnosis
HPV the silent killer, Prevention and diagnosis HPV Human Papilloma Virus is a name given for a silent virus transmitted sexually most of the time, a virus that spreads in the name of love, passion, and
More informationThe Global Burden of HPV Related Cancers and Their Prevention
The Global Burden of HPV Related Cancers and Their Prevention What Every Doctor Should Know! Dr. Adrian Lear, MD Conflict of Interest Disclosure I have no financial relations with any commercial entity
More informationQuadrivalent Human Papillomavirus Vaccine
INVITED ARTICLE VACCINES Bruce Gellin and John F. Modlin, Section Editors Quadrivalent Human Papillomavirus Vaccine Eliav Barr and Gretchen Tamms Merck Research Laboratories, West Point, Pennsylvania The
More informationHuman papilloma viruses and cancer in the post-vaccine era
REVIEW 10.1111/j.1469-0691.2009.03032.x Human papilloma viruses and cancer in the post-vaccine era E. Galani and C. Christodoulou Metropolitan Hospital Medical Oncology, Athens, Greece Abstract Human papilloma
More informationHPV - From Warts to Cancer
12/26/217 HPV Infection Immunizing for Cancer Prevention Paul J Carson, MD, FACP Professor, Dept. of Public Health North Dakota State University Epidemiology and Pathology HPV Genotypes and Their Disease
More informationGSK Medication: Study No.: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationOPPORTUNISTIC HPV VACCINATION: AN EXPANDED VISION
OPPORTUNISTIC HPV VACCINATION: AN EXPANDED VISION SUMMARY POSITION Human papillomavirus (HPV) infection is preventable but not adequately prevented. At present, Canada has a robust school vaccination program
More informationHPV Vaccine Safety & Effectiveness
HPV Vaccine Safety & Effectiveness 2006 2017 2006 1 2 June 1. US Food and Drug Administration (FDA) approves Gardasil for the prevention of cervical cancer, and precancerous lesions by HPV types 6, 11,
More informationPresenter Disclosure Information
1:30 2:25pm An Update on HPV Cancer Prevention SPEAKERS Kenneth Alexander, MD, PhD Anna Giuliano, PhD Presenter Disclosure Information The following relationships exist related to this presentation: Dr
More informationProphylactic HPV Vaccines. Margaret Stanley Department of Pathology Cambridge
Prophylactic HPV Vaccines Margaret Stanley Department of Pathology Cambridge 8kb double stranded DNA viruses, absolutely host and tissue specific, Can t grow virus in tissue culture Classified by genotype
More informationChapter 13: Current findings from prophylactic HPV vaccine trials
Vaccine 24S3 (2006) S3/114 S3/121 Chapter 13: Current findings from prophylactic HPV vaccine trials Laura A. Koutsky a,, Diane M. Harper b a Department of Epidemiology, School of Public Health, University
More informationHPV vaccination: the promise & problems
Review Article Indian J Med Res 130, September 2009, pp 322-326 vaccination: the promise & problems R. Sankaranarayanan Screening Group, International Agency for Research on Cancer, Lyon, France Received
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More information32 OBG Management May 2015 Vol. 27 No. 5 obgmanagement.com
The Advisory Committee on Immunization Practices recommends routine vaccination against HPV in 11- and 12-year-olds, although the age can range from 9 to 26 years (for those who have not been vaccinated
More informationGARDASIL [Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine]
` Page 1 of 17 PRODUCT CIRCULAR GARDASIL [Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine] I. THERAPEUTIC CLASS GARDASIL is a recombinant, quadrivalent vaccine that protects
More informationHuman papilloma virus vaccines
Many Hearts Many Minds One Goal Volume 3 Number 4 September 2007 Human papilloma virus vaccines New horizons in the prevention of cervical cancer By Shelly A. McNeil MD, FRCPC, Canadian Centre for Vaccinology,
More informationQuick Reference: Immunization Communication Tool For Immunizers HPV 2010
Quick Reference: Immunization Communication Tool For Immunizers HPV 2010 Are young girls being used as guinea pigs for an unproven vaccine? Client knowledge NO. In both clinical trials conducted for the
More informationIn February 2007, the National Advisory Committee on
ADULT INFECTIOUS DISEASE NOTES The human papillomavirus vaccine: The promise of cervical cancer prevention BL Johnston MD 1, JM Conly MD 2 In February 2007, the National Advisory Committee on Immunization
More informationRESEARCH. Economic evaluation of human papillomavirus vaccination in the United Kingdom
Economic evaluation of human papillomavirus vaccination in the United Kingdom Mark Jit, health economist and mathematical modeller, Yoon Hong Choi, mathematical modeller, WJohnEdmunds,headofmodellingandeconomicsunit
More informationLECTURE: human papilloma virus vaccine
LECTURE: human papilloma virus vaccine Editing File Important Doctor s notes Extra explanation Only F or only M وتقال هذه الجملة إذا "ال حول وال قوة إال باهلل العلي العظيم ".داهم اإلنسان أمر عظيم ال يستطيعه
More informationWoo Dae Kang, Ho Sun Choi, Seok Mo Kim
Is vaccination with quadrivalent HPV vaccine after Loop Electrosurgical Excision Procedure effective in preventing recurrence in patients with High-grade Cervical Intraepithelial Neoplasia (CIN2-3)? Chonnam
More informationPrevalence of human papillomavirus in men who have sex with men in the era of an effective vaccine; a call to act
DOI: 10.1111/hiv.12150 ORIGINAL RESEARCH Prevalence of human papillomavirus in men who have sex with men in the era of an effective vaccine; a call to act C Sadlier, 1 D Rowley, 1 D Morley, 1 S Surah,
More informationHPV Vaccine Ina Park, MD, MS
HPV Vaccine Ina Park, MD, MS California Department of Public Health STD Control Branch Alameda County Immunization Update 2014 Over 170 types of HPV classified Updated incidence/prevalence estimates (CDC):
More informationAntigen Literature Review for the New Zealand National Immunisation Schedule, 2016: Human papillomavirus
Antigen Literature Review for the New Zealand National Immunisation Schedule, 2016: Human papillomavirus Prepared as part of a Ministry of Health contract for services by the Immunisation Advisory Centre
More informationNo type-replacement following papillomavirus vaccination. The National Medicine 2012 Convention 12 January /08/2012 Marko Merikukka 2
No type-replacement following papillomavirus vaccination The National Medicine 2012 Convention 12 January 2012 28/08/2012 Marko Merikukka 1 Introduction (1) We cannot predict whether HPV mass vaccination
More informationF.C. Shakhtatinskaya, L.S. Namazova-Baranova, V.K. Tatochenko, D.A. Novikova, T.E. Tkachenko
F.C. Shakhtatinskaya, L.S. Namazova-Baranova, V.K. Tatochenko, D.A. Novikova, T.E. Tkachenko Scientific Center of Children s Health, Moscow, Russian Federation Human Papilloma Virus. Prevention of HPV-Associated
More informationHPV vaccination: How long does the protection really last? Joakim Dillner
HPV vaccination: How long does the protection really last? Joakim Dillner Professor of Infectious Disease Epidemiology PI, International HPV Reference Center Director, Swedish Cervical Cancer Prevention
More informationVIRUS VACCINES & CANCER a story with two chapters
VIRUS VACCINES & CANCER a story with two chapters F X BOSCH Institut Catala d Oncologia Sant Pau 2017 Potential conflict of interest Research and educational institutional grants: GSK, SPMSD, Merck, Qiagen
More informationBeneficial Effects of Human Papillomavirus Vaccine for Prevention of Cervical Abnormalities in Miyagi, Japan
Tohoku J. Exp. Med., 2016, 240, 147-151 Beneficial Effects of Vaccine on Cervical Abnormalities 147 Beneficial Effects of Human Papillomavirus Vaccine for Prevention of Cervical Abnormalities in Miyagi,
More informationHPV infections and potential outcomes
CONTENTS Preface by Silvia de Sanjosé... 33 Preface by Jacob Bornstein... 37 Author s note... 39 Acknowledgments... 45 CHAPTER 1 HPV infections and potential outcomes HPV: What it is, where it is and what
More informationMEDICAL ADVISOR REPORT TT /1
I.1 Type NMA (abbreviated) MEDICAL ADVISOR REPORT TT50-7571/1 I.2 Medication Gardasil; Human Papillomavirus 9-valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) vaccine. The HPV vaccine is an aluminium adjuvanted
More informationCervical screening. Cytology-based screening programmes
HPV-FASTER: broadening the scope for prevention of HPV-related cancer Combining the complementary approaches of HPV vaccination and screening could accelerate declines in the burden of cervical cancer
More informationHuman Papillomavirus. Kathryn Thiessen, ARNP, ACRN The Kansas AIDS Education and Training Center The University of Kansas School of Medicine Wichita
Human Papillomavirus Kathryn Thiessen, ARNP, ACRN The Kansas AIDS Education and Training Center The University of Kansas School of Medicine Wichita What is Genital HPV Infection Human papillomavirus is
More informationCrisis in US Health Care Failure of Primary HPV related Cancer Prevention. Learning Objectives. 4. Encourage the use the HPV vaccine
Crisis in US Health Care Failure of Primary HPV related Cancer Prevention Daron G. Ferris, MD Professor Department of Obstetrics and Gynecology Georgia Regents University Cancer Center Georgia Regents
More informationCERVICAL CANCER FACTSHEET. What is cervical cancer?
CERVICAL CANCER FACTSHEET What is cervical cancer? ENGAGe is releasing a series of factsheets to raise awareness of gynaecological cancers and to support its network to work at a grassroots level. Take-up
More informationCervical Cancer Screening - Improving PAP Rates. Objectives
Cervical Cancer Screening - Improving PAP Rates Dineo Khabele, MD, FACOG, FACS Assistant Professor Division of Gynecologic Oncology Vanderbilt University Medical Center Objectives 1. Review the current
More informationO RIGINAL P APER. Extending Quadrivalent Human Papilloma Virus (HPV) Vaccination To Males What Is The Current Evidence?
O RIGINAL P APER Extending Quadrivalent Human Papilloma Virus (HPV) Vaccination To Males What Is The Current Evidence? T H E S I N G A P O R E F A M I L Y P H Y S I C I A N V O L 4 1(3) J U L - S E P 2
More informationSAGE evidence to recommendations framework i
SAGE evidence to recommendations framework i Question: What is the public health impact on cervical cancer of administering HPV vaccine to 9 to 15-year old females and males versus to 9 to 15-year old
More informationQuadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases
T h e n e w e ng l a nd j o u r na l o f m e dic i n e original article Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases Suzanne M. Garland, M.D., Mauricio Hernandez-Avila,
More informationHuman Papillomavirus: Should Males be Immunized Too?
Human Papillomavirus: Should Males be Immunized Too? Cheryl Holt, Pharm.D. PGY1 Pharmacy Resident South Texas Veterans Health Care System The University of Texas at Austin College of Pharmacy The University
More informationGARDASIL 9 Human Papillomavirus 9-valent Vaccine, Recombinant
SWISS SUMMARY OF ACTIVITIES IN THE RISK MANAGEMENT PLAN FOR GARDASIL 9 Human Papillomavirus 9-valent Vaccine, Recombinant Active Substance: Human Papillomavirus 9-valent Vaccine, Recombinant MAH / MAA
More informationHPV/Cervical Cancer Resource Guide for patients and providers
DHS: PUBLIC HEALTH DIVISION IMMUNIZATION PROGRAM HPV/Cervical Cancer Resource Guide for patients and providers Independent. Healthy. Safe. Oregon HPV Provider Resource Kit: Table of Contents Provider Information
More informationCarolyn Johnston, MD Clinical Professor University of Michigan and St. Joseph Mercy Hospital Gynecologic Oncology Sept 2014
Carolyn Johnston, MD Clinical Professor University of Michigan and St. Joseph Mercy Hospital Gynecologic Oncology Sept 2014 HPV is the most common sexually transmitted infection in the USA Small DNA virus
More information2017 Human Papillomavirus Immunisation Programme
2017 Human Papillomavirus Immunisation Programme 1 1 HPV infection HPV is a virus that infects the skin and mucous membranes Most infections clear within 18 months Clearing infection does not confer immunity
More informationThe new European (and Italian) guidelines for cervical screening will recommend PAP from 25 to 34 HPV (+ triage) from 35 to 64
The new European (and Italian) guidelines for cervical screening will recommend PAP from 25 to 34 HPV (+ triage) from 35 to 64 risk of overdiagnosis and over treatment Failures in reproductive functioning:
More informationHuman Papillomaviruses and Cancer: Questions and Answers. Key Points. 1. What are human papillomaviruses, and how are they transmitted?
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Human Papillomaviruses
More informationFollowing microtrauma, HPV s bind to the basement membrane, infect basal cells, and replicate in suprabasal cells
Following microtrauma, HPV s bind to the basement membrane, infect basal cells, and replicate in suprabasal cells Virion Assembled Virus Stratified squamous epithelium Virion Suprabasal cells HPV DNA replication
More informationHPV Infection and associated disease among HIV positive individuals. Admire Chikandiwa. Wits RHI
HPV Infection and associated disease among HIV positive individuals Admire Chikandiwa Wits RHI Outline of presentation Introduction Burden of HPV associated diseases The role of HIV and its interaction
More informationReview Article. Abstract. Introduction. HPV Pathogenesis:
Review Article Prevention of human papilloma virus infection with vaccines Faisal Azam, Mohammad Shams-ul-Islam Medical Oncology, Churchill Hospital, Oxford, United Kingdom. Abstract Human Papilloma virus
More informationHPV Vaccines. What is HPV? Can a vaccine help prevent HPV?
What is HPV? HPV Vaccines HPV is short for human papilloma virus. HPVs are a group of more than 150 related viruses. Each HPV virus in the group is given a number, which is called an HPV type. HPVs are
More informationPAP smear. (Papanicolaou Test)
PAP smear (Papanicolaou Test) Is a screening test to prevent/ detect cancerous processes in endocervical canal It reduces the mortality caused by cervical cancer up to 80% M. Arbyn; et al. (2010). "European
More information